跳至主要内容
临床试验/JPRN-UMIN000006197
JPRN-UMIN000006197已完成3 期

Therapeutic fficacy of sitagliptin in patients with nonalcoholic fatty liver disease (NAFLD)in impaired glucose tolerance (IGT): a pilot study. - Efficacy of sitagliptin in NAFLD patients with IGT

Iwasaki Naika Clinic0 个研究点目标入组 20 人开始时间: 2011年9月1日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • a.The criteria for exclusion from participation in the study: history of hepatic disease, such as chronic hepatitis C or concurrent active hepatitis B (serum positive for hepatitis B surface antigen), autoimmune hepatitis, primary biliary cirrhosis (PBC), sclerosing cholangitis, hemochromatosis, alpha1-antitrypsin deficiency, Wilsons disease, and current or past consumption of more than 20 g of alcohol daily. b. None of the patients had any clinical evidence of hepatic decompensation, such as hepatic encephalopathy, ascites, variceal bleeding, or elevated serum bilirubin level to more than twofold the upper limit of normal.

研究者

相似试验